ImpriMed, a top precision medicine startup using AI for cancer treatment advancement, shared its participation in the World Veterinary Cancer Congress (WVCC) 2024 in Tokyo, Japan, from March 21-24, 2024. CEO Dr. Sungwon Lim and CTO Dr. Jamin Koo will present an oral abstract and scientific poster, respectively. They will showcase data demonstrating the efficacy of personalized drug response predictions in treating lymphoma in dogs and cats.
On March 21, 2024, at 5pm JST, Dr. Sungwon Lim will lead ImpriMed’s participation at the World Veterinary Cancer Congress (WVCC) with an oral abstract presentation titled “Enhancing Clinical Outcomes in Canine Lymphoma with AI Decision Support.” This presentation will summarize ImpriMed’s study published in Frontiers in Oncology, showcasing AI-driven drug response predictions’ effectiveness in treating canine lymphoma. The study utilized AI models to predict treatment outcomes for dogs with high-grade T-cell lymphoma (hTCL) and relapsed B-cell lymphoma (rBCL), yielding significant results:
- Dogs with a high AI-predicted treatment match showed significantly increased remission rates compared to the low-matching group, for both hTCL (9.1% low, 59% high) and rBCL (13% low, 53% high).
- rBCL patients in the high-matching group demonstrated superior clinical outcomes across all analyzed metrics compared to the low-matching group and historical controls.
These findings underscore AI’s potential to enhance clinical outcomes and transform veterinary oncology, as highlighted by Dr. Lim’s presentation.
Additionally, Dr. Jamin Koo will present a scientific poster titled “Personalized Treatment Approaches for Feline Lymphoma Using AI-Driven Flow Cytometry Analyses,” emphasizing ImpriMed’s commitment to personalized feline lymphoma treatment. This poster outlines how AI in flow cytometry analyses aids in treatment-specific risk stratification for feline lymphoma.
Dr. Lim expressed, “We are excited to showcase AI’s transformative impact at the World Veterinary Cancer Congress, advancing standards of care in veterinary oncology globally. Our goal is to foster collaboration and innovation within the field to drive industry progress.”
ImpriMed will also host an exhibit booth during the conference as a bronze-level sponsor, providing attendees with further insights into their personalized drug response predictions’ capabilities and their role in improving patient outcomes.
